Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) have received an average recommendation of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $30.97.

A number of brokerages have weighed in on JUNO. Vetr upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $28.85 target price for the company in a report on Monday. Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Tuesday, July 11th. BidaskClub upgraded Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 27th. Wedbush restated a “neutral” rating and set a $24.00 price objective on shares of Juno Therapeutics in a report on Tuesday, June 6th. Finally, BTIG Research downgraded Juno Therapeutics from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $12.00 to $23.00 in a report on Tuesday, June 6th.

In other Juno Therapeutics news, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total value of $262,500.00. Following the transaction, the chief financial officer now owns 736,189 shares of the company’s stock, valued at $22,085,670. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Anthony B. Evnin acquired 9,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was acquired at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the transaction, the director now owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The disclosure for this purchase can be found here. In the last three months, insiders sold 41,500 shares of company stock worth $1,230,360. Insiders own 15.26% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of JUNO. Great West Life Assurance Co. Can boosted its position in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares in the last quarter. Nisa Investment Advisors LLC acquired a new position in Juno Therapeutics during the first quarter valued at $200,000. Russell Investments Group Ltd. acquired a new position in Juno Therapeutics during the fourth quarter valued at $204,000. Tudor Investment Corp Et Al acquired a new position in Juno Therapeutics during the fourth quarter valued at $215,000. Finally, Opus Point Partners Management LLC boosted its position in Juno Therapeutics by 65.9% in the fourth quarter. Opus Point Partners Management LLC now owns 11,478 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 4,560 shares in the last quarter. 64.51% of the stock is currently owned by institutional investors and hedge funds.

Juno Therapeutics (NASDAQ JUNO) opened at 27.26 on Monday. The company has a 50 day moving average price of $24.94 and a 200 day moving average price of $22.57. The firm’s market capitalization is $2.84 billion. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $35.04.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by $0.01. The business had revenue of $19.30 million during the quarter, compared to the consensus estimate of $16 million. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The company’s revenue for the quarter was up 96.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.78) earnings per share. Analysts anticipate that Juno Therapeutics will post ($2.99) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Receives Average Rating of “Buy” from Analysts” was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/juno-therapeutics-inc-juno-receives-average-rating-of-buy-from-analysts/1444424.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.